Need for plasma angiotensin measurements to investigate converting-enzyme inhibition in humans

Détails

ID Serval
serval:BIB_A5F9CCE2795A
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Need for plasma angiotensin measurements to investigate converting-enzyme inhibition in humans
Périodique
American Heart Journal
Auteur⸱e⸱s
Nussberger  J., Juillerat  L., Perret  F., Waeber  B., Bellet  M., Brunner  J., Menard  J.
ISSN
0002-8703 (Print)
Statut éditorial
Publié
Date de publication
03/1989
Volume
117
Numéro
3
Pages
717-22
Notes
Clinical Trial
Comparative Study
Journal Article --- Old month value: Mar
Résumé
Since only a minute proportion of total angiotensin-converting enzyme (ACE) is present in plasma, the reliability of conventional in vitro measurements of ACE activity has been questioned. Data presented here demonstrate that the definition of ACE inhibition depends on the methodology used, with different results obtained with different substrates. We have developed a method that provides accurate and precise determinations of "true" angiotensin levels and in vivo ACE activity was estimated by measuring the plasma angiotensin II/angiotensin I ratio. Since the initial interruption of angiotensin II production by an ACE inhibitor stimulates renal renin release, the response can be quantitated by measuring changes in plasma levels of angiotensin I. The actual state of the renin-angiotensin system during ACE inhibition is represented by the plasma angiotensin II level. When ACE inhibition is no longer complete, increased angiotensin I levels bring the system back toward initial angiotensin II concentrations.
Mots-clé
Administration, Oral Adult Angiotensin I/*blood Angiotensin II/*blood Angiotensin-Converting Enzyme Inhibitors/*pharmacology Benzazepines/pharmacology Blood Pressure/*drug effects Clinical Trials Enalapril/pharmacology Humans
Pubmed
Web of science
Création de la notice
05/03/2008 17:41
Dernière modification de la notice
20/08/2019 16:11
Données d'usage